Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMML3XI)

Drug Name

2-(1-benzyl-1H-indol-3-yl)-N,N-dimethylethanamine Drug Info

Synonyms

CHEMBL188144; 2-(1-benzyl-1H-indol-3-yl)-N,N-dimethylethanamine; BDBM50164758

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting 5-HT 6 receptor (HTR6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LU AE58054	DMWGRQD	Schizophrenia	6A20	Phase 3	[2]
SB-742457	DM6L4ZT	Alzheimer disease	8A20	Phase 3	[3]
AVN 211	DMVB4OS	Schizophrenia	6A20	Phase 2/3	[4]
SYN120	DMDF7XB	Parkinson disease	8A00.0	Phase 2	[5]
AVN 101	DMJFLBC	Alzheimer disease	8A20	Phase 2	[4]
SYN-120	DMPW0UL	Alzheimer disease	8A20	Phase 2	[6]
PF-05212377	DMPVQYR	Alzheimer disease	8A20	Phase 2	[7]
AVN 322	DMK2LGM	Cognitive impairment	6D71	Phase 2	[3]
SAM-531	DMHVJZ6	Alzheimer disease	8A20	Phase 2	[8]
SUVN-502	DMQD753	Alzheimer disease	8A20	Phase 2	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Indene-based scaffolds. 2. An indole-indene switch: discovery of novel indenylsulfonamides as 5-HT6 serotonin receptor agonists. J Med Chem. 2009 Feb 12;52(3):675-87.
2	Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol. 2010 Sep;13(8):1021-33.
3	5-HT6 receptors and Alzheimer's disease. Alzheimers Res Ther. 2013; 5(2): 15.
4	Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea. Curr Opin Investig Drugs. 2010 January; 11(1): 80-91.
5	Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat Rev Drug Discov. 2018 Nov;17(11):804-822.
6	The Serotonin-6 Receptor as a Novel Therapeutic Target. Exp Neurobiol. 2011 December; 20(4): 159-168.
7	PF-05212377 Alzheimer's Disease (Phase 2). Pfizer.
8	Activation of 5-HT6 receptors modulates sleep-wake activity and hippocampal theta oscillation. ACS Chem Neurosci. 2013 Jan 16;4(1):191-9.
9	Novel and Potent 5-Piperazinyl Methyl-N1-aryl Sulfonyl Indole Derivatives as 5-HT6 Receptor Ligands. ACS Med Chem Lett. 2010 October 14; 1(7): 340-344.